

# Session 3 – GMP and Market Control: Control of the market place

Anna O'Brien, DVM  
Veterinary Medical Officer  
U.S. Food and Drug Administration  
Center for Veterinary Medicine



5<sup>th</sup> Global Animal Health  
Conference and Workshop 2016

Improved Market Access for Authorised  
Veterinary Medicines – The Asian Perspective

Organising Committee:

BILL & MELINDA  
GATES foundation

EUROPEAN MEDICINES AGENCY  
SCIENCE • MEDICINES • HEALTH

FDA

OIE  
WORLD ORGANISATION  
FOR ANIMAL HEALTH

GALVmed  
Protecting Livestock – Improving Human Lives

International Federation of Animal Health  
INFFH

Health for Animals  
global animal medicines association

DIA DEVELOP  
INNOVATE  
ADVANCE



# Control of the market place

- ▶ Importance of a regulatory system that enforces control of the market place for veterinary products:
  - Protects consumers, animal health, farmers, public health, food supply
  - Provides level of consumer confidence
    - Promotes consumer trust
    - Encourages/supports economic growth





# Control of the market place

- ▶ Many ways a regulatory authority can implement market control
  - Import/export controls
  - Finding and acting on counterfeit products
  - Pharmacovigilance

**Post-authorization monitoring is just as important as pre-market review!**



# Keys to success

- ▶ Implementing a set of **reliable, robust, predictable, transparent** regulatory systems
- ▶ Communication is vital so everyone knows what to expect
  - Unpredictability and inconsistencies hinder cooperation; locally, nationally, and internationally
- ▶ Can be organized through:
  - Local laws/regulations
  - International guidance/agreements
  - Industry pharmaceutical organizations



# Imports

- ▶ Import control:
  - Provides awareness of the imported products
  - Provides awareness of the national regulations which apply to those imported products

**Main benefit:**  
**Minimal delay at the port of entry**



# Imports

- ▶ Imports aren't just final marketed products. Also could include
  - ▶ Bulk API
    - ▶ Vast majority of bulk API for national pharmaceutical manufacturers may be from international imports

For bulk API imports, consider:

- Is approval of the imported drug in progress?
- Is the API manufacturer an approved source under an approved application?
- Is the local manufacturer an approved company under an approved application?

**Understanding the supply chain is key**



# Imports

- ▶ Control at the port of entry – might be through different regulatory sectors (may involve tariffs, fees, bonds, etc).
- ▶ Consistent training of investigators at ports is crucial for success
- ▶ Aspects to consider:
  - What training is required?
  - What are consequences of illegal importation?
  - What happens to the import itself if deemed illegal?
  - Communicate clearly to stakeholders any new requirements/changes in process



# Exports

- ▶ What is the purpose of export certificates?
  - Official assurance that products meet specific regulations (like cGMP)
  
- ▶ When to refuse to issue an export certificate?
  - When products don't meet applicable requirements
  - When enforcement action has occurred
  - Non-compliance with cGMP
  - Manufacturing facilities aren't registered








# Exports

- ▶ Export certificates—many types, depending on what is being exported.
- ▶ Examples:
  - For approved new animal drugs and medicated feed or food additives—certificates to foreign government
  - For unapproved new animal drugs and feed products not approved—certificates of exportability
  - For approved new animal drug products—certificates of a pharmaceutical product



# Counterfeits

- ▶ A definition: an API or finished drug product that bears a label or other representation declaring that it was manufactured, processed, distributed or packed by a company which did not in fact manufacture, process, distribute or pack it.





# Counterfeits

## ▶ However...

- Definitions of counterfeit drugs vary from country to country
- These differences give rise to discrepancies in enforcement






# Counterfeits

- ▶ Counterfeit sales estimated at \$75 billion globally (2011)
- ▶ Weak local drug regulation, enforcement and even corruption in some countries
- ▶ Serious public health significance:
  - Harmful impurities
  - May be ineffective
  - Undermines integrity of drug authorization process

# Adulterated Sulfamethoxazole

Detected by the  
Australian Therapeutic Goods Administration





# Infrastructure needed for counterfeit detection

- ▶ Forensic chemistry center
  - Provides analytical techniques for government agencies
    - Atomic/molecular spectroscopy
    - Microscopy
    - Chromatography/mass spectrometry
- ▶ Creating a database
- ▶ Examining Certificates of Analysis, packaging, labels



# Testing options – CD-3 (FDA counterfeit detection device)



**Counterfeit**

**Comparison of Features of Authentic PROCIT and Counterfeit Product Bearing Lot Number P004677, expiration 02/2004.**



**Authentic PROCIT vial P004677.**  
Aluminum wrap under red cap is smooth without dents.



**Counterfeit product vial P004677.**  
Aluminum wrap under red cap is not smooth and may appear to be dented.





**Serono**

# Serostim<sup>®</sup> 6 mg

[somatotropin (rDNA origin) for injection]

Storage : room temperature (15°-30°C/59°-86°F)  
Use within 24 hours of reconstitution. Discard unused material.  
Manufactured for: Serono Laboratories, Inc. Randolph, MA 02368, USA  
by : DuPont Pharma, Wilmington, DE 19880

For subcutaneous injection

AS2050 09/98

**MNK612A**  
**08-01**

**Serono**

# Serostim<sup>®</sup> 8 mg

[somatotropin (rDNA origin) for injection]  
Storage: Room temperature (15°-30°C/59°-86°F)  
Use within 24 hours of reconstitution. Discard unused material.  
Manufactured for: Serono Laboratories, Inc.  
Randolph, MA 02368, USA  
by: Dupon Pharms, Wilmington, De 1980

For subcutaneous injection

AS2050 09/98

**MNK612A**  
**08/02**



**Counterfeit**



# Counterfeits

- ▶ General considerations:
  - Understand the supply chain
  - Test incoming raw materials
  - Adequate sampling plan



# Pharmacovigilance

- ▶ Defined by the World Health Organization as the science and activities related to the detection, assessment, understanding and prevention of adverse drug effects or any other possible drug-related problems.





# Pharmacovigilance

- ▶ Monitor reports of adverse drug events and product defects
  - Reports are received from:
    - Marketing Authorization Holders
    - Veterinarians
    - Animal owners
- ▶ Can result in changes in product labeling or other regulatory action
  - Better communication for drug safety information
- ▶ How to implement?
  - Require reporting by law/regulation
  - Voluntary reporting from public
  - Refer to VICH guidance documents on collecting information



# Pharmacovigilance

- ▶ Periodic summary reports are supplied by Marketing Authorization Holders for continued marketing
- ▶ Requires infrastructure – flow of information
  - How to report?
  - Who will review reports (both adverse event reports and periodic summary reports)
  - What action will be taken?
  - By whom?



# Conclusions

- ▶ Market control is a vital aspect of the regulatory process
  - Protecting human and animal health
- ▶ Requires training, budget, resources
- ▶ Leverage international resources





# Thank you!